Lataa...
Drug–drug interactions during antiviral therapy for chronic hepatitis C
The emergence of direct-acting antiviral agents (DAAs) for HCV infection represents a major advance in treatment. The NS3 protease inhibitors, boceprevir and telaprevir, were the first DAAs to receive regulatory approval. When combined with PEG-IFN and ribavirin, these agents increase rates of susta...
Tallennettuna:
| Julkaisussa: | Nat Rev Gastroenterol Hepatol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4634866/ https://ncbi.nlm.nih.gov/pubmed/23817323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrgastro.2013.106 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|